首页> 外国专利> METHOD OF DIAGNOSIS hepatocellular carcinoma (SCC), PROCESS EVALUATION OF THE EFFECTIVENESS OF TREATMENT nucleotide sequence, protein, antibody and gene for PAC DIAGNOSTICS, METHOD FOR SCREENING COMPOUNDS FOR TREATMENT GAC METHOD FOR DIAGNOSIS OF INITIAL STAGES GAC nucleotide sequence PROTEIN ANTIBODY AND GENE FOR DIAGNOSIS OF THE INITIAL STAGE OF THE GAC, A METHOD FOR SCREENING THE CONNECTION FOR THE DIAGNOSTICS OF THE INITIAL STAGE OF THE GAC, A SOLID CARRIER, A SET AND KIT AS A MEANS FOR DIAGNOSTIC OF THE GAC AND THE INITIAL STAGE OF THE GAC

METHOD OF DIAGNOSIS hepatocellular carcinoma (SCC), PROCESS EVALUATION OF THE EFFECTIVENESS OF TREATMENT nucleotide sequence, protein, antibody and gene for PAC DIAGNOSTICS, METHOD FOR SCREENING COMPOUNDS FOR TREATMENT GAC METHOD FOR DIAGNOSIS OF INITIAL STAGES GAC nucleotide sequence PROTEIN ANTIBODY AND GENE FOR DIAGNOSIS OF THE INITIAL STAGE OF THE GAC, A METHOD FOR SCREENING THE CONNECTION FOR THE DIAGNOSTICS OF THE INITIAL STAGE OF THE GAC, A SOLID CARRIER, A SET AND KIT AS A MEANS FOR DIAGNOSTIC OF THE GAC AND THE INITIAL STAGE OF THE GAC

机译:诊断肝细胞癌(SCC)的方法,治疗核苷酸序列,蛋白质,抗体和基因对PAC诊断的有效性评估过程,筛选治疗GAC化合物的方法初步诊断GAC核苷酸序列蛋白质抗体和诊断基因的方法GAC的初始阶段,一种用于筛选GAC的初始阶段,固体载体,集合和工具包作为GAC的诊断方法和GAC的初始阶段的诊断方法之间的联系的方法

摘要

1. A method of diagnosing hepatic cell carcinoma (PAC) in vitro in a subject or assessing a subject's predisposition to develop PAC or to assess the prognosis of PAC in a subject or to determine the stage or severity of PAC in a subject, characterized in that the expression level is measured, at least , of a single gene in a liver tissue sample of said subject, said level of gene expression is compared with the level of expression of the same gene in a control sample and a decrease in said level of gene expression compared to exp resitions of the same gene in the control sample as a symptom of PAC, alternatively measure the level of at least one protein in the liver tissue sample of said subject, compare said protein level with the level of the same protein in the control sample, and consider a decrease in said expression level of the gene compared with the level of expression of the same gene in the control sample as a symptom of PAC, wherein said gene is selected from the group comprising a gene that encodes alcohol dehydrogenase (ADH) [ADH gene], a gene that encodes antioxidant protein 2 (AOP2) [AOP2 gene], a gene that encodes regularcalcin (SMP30) [SMP30 gene], a gene that encodes a non-specific sterol-transporting protein (NSLT) [NSLT gene], a gene that encodes sorbitol dehydrogenase (SDH) [ SDH gene], a gene that encodes serum albumin (SAP) [SAP gene], a gene that encodes phosphoglucomutase (PGM) [PGM gene], a gene that encodes phenylalanine-4-hydroxylase (P4H) [P4H gene], a gene that encodes apolipoprotein A1 (APOA1) [APOA1 gene], a gene that encodes carbonic anhydrase III (CAIII) [CAIII gene], a gene that encodes mitochondrial aldehyde
机译:1.一种在受试者中体外诊断肝细胞癌(PAC)或评估受试者罹患PAC的倾向或评估受试者中PAC的预后或确定受试者中PAC的阶段或严重性的方法,其特征在于:至少测量所述受试者的肝组织样品中单个基因的表达水平,将所述基因表达水平与对照样品中相同基因的表达水平进行比较,并将所述水平降低。将基因表达与对照样品中相同基因的表达作为PAC的症状进行比较,或者测量所述受试者的肝组织样品中至少一种蛋白质的水平,将所述蛋白质水平与相同蛋白的水平进行比较对照样品,并考虑与作为PAC症状的对照样品中相同基因的表达水平相比,该基因的表达水平降低,其中所述基因选自组编码酒精脱氢酶(ADH)的基因[ADH基因],编码抗氧化蛋白2(AOP2)的基因[AOP2基因],编码正钙蛋白(SMP30)的基因[SMP30基因],该基因编码非特定固醇转运蛋白(NSLT)[NSLT基因],一种编码山梨糖醇脱氢酶(SDH)的基因[SDH基因],一种编码血清白蛋白(SAP)的基因[SAP基因],一种编码磷酸葡萄糖突变酶(PGM)的基因[ [PGM基因],一种编码苯丙氨酸-4-羟化酶(P4H)的基因[P4H基因],一种编码载脂蛋白A1(APOA1)的基因[APOA1基因],一种编码碳酸酐酶III(CAIII)的基因[CAIII基因],编码线粒体醛的基因

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号